News – Page 5 – Alligator Bioscience

2023-04-27

Alligator Bioscience & Amphera Announce Last Patient Treated in mitazalimab-MesoPher REACTIVE-2 Phase 1 Study in Pancreatic Cancer

REACTIVE-2 is assessing the safety and immunological effect of mitazalimab in combination with MesoPher in metastatic pancreatic cancer Mita ...

2023-04-262023-04-26

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-04-26

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2023-04-25

Mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer completes enrolment following positive interim results; top-line data due Q1 2024 ...

2023-04-24

Regulatory

Today, on 24 April 2023, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...

2023-04-18

Presentation highlights potential of ATOR-4066 to induce strong anti-tumor responses in patients with CEACAM5-expressing tumors Data strongl ...

2023-04-12

OPTIMIZE-1 is assessing the safety and efficacy of mitazalimab in combination with mFOLFIRINOX in 1st line metastatic pancreatic cancer Inte ...

2023-04-03

OPTIMIZE-2 is a Phase 2 study to assess the safety and efficacy of mitazalimab in combination with a PD-1 inhibitor in patients affected by ...

2023-03-24

Regulatory

Lund, Sweden, March 24, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2022 has been publi ...